Scholarlink

<p>Ebola virus (EBOV), a member of the <i>Filoviridae</i> family, is responsible for severe hemorrhagic fever outbreaks with high case fatality rates in humans. Although injectable vaccines have shown efficacy, their deployment remains challenging in outbreak settings due to cold-chain requirements and the need for trained personnel. Oral vaccination offers an attractive alternative, combining ease of administration with the potential to induce both mucosal and systemic immunity. In this study, we evaluated the immunogenicity and protective efficacy of an orally-administered Ebola virus filovirus-like particle (EBOV-VLP) vaccine in type I interferon receptor-deficient (IFNAR<sup>−</sup>/<sup>−</sup>) mice. Mice received one or three oral doses of EBOV-VLP prior to intranasal challenge with a lethal dose of EBOV. Our data demonstrate that oral immunization with EBOV-VLP elicits specific humoral immune responses and confers partial protection against lethal EBOV infection. These findings support further exploration of VLP-based oral vaccines as a potential component of EBOV disease preparedness strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oral immunization with filovirus-like particles partially protects IFNAR−/− mice against lethal ebola virus challenge

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Beatriz Escudero-Pérez,
  • Fátima Lasala,
  • Joanna Luczkowiak,
  • Nuria Labiod,
  • Gonzalo Rivas,
  • Hugo Morgado,
  • José M. Casasnovas,
  • Julia Nave,
  • Stephanie Wurr,
  • Juan García-Bernalt Diego,
  • César Muñoz-Fontela,
  • Rafael Delgado

摘要

Ebola virus (EBOV), a member of the Filoviridae family, is responsible for severe hemorrhagic fever outbreaks with high case fatality rates in humans. Although injectable vaccines have shown efficacy, their deployment remains challenging in outbreak settings due to cold-chain requirements and the need for trained personnel. Oral vaccination offers an attractive alternative, combining ease of administration with the potential to induce both mucosal and systemic immunity. In this study, we evaluated the immunogenicity and protective efficacy of an orally-administered Ebola virus filovirus-like particle (EBOV-VLP) vaccine in type I interferon receptor-deficient (IFNAR−/−) mice. Mice received one or three oral doses of EBOV-VLP prior to intranasal challenge with a lethal dose of EBOV. Our data demonstrate that oral immunization with EBOV-VLP elicits specific humoral immune responses and confers partial protection against lethal EBOV infection. These findings support further exploration of VLP-based oral vaccines as a potential component of EBOV disease preparedness strategies.